Comparative Pharmacology
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOXACILLIN SODIUM versus PROBAMPACIN.
DICLOXACILLIN SODIUM vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicloxacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and leading to cell lysis. It is resistant to penicillinase-producing organisms.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
125-500 mg orally every 6 hours
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates, elderly, or severe renal impairment.
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Primarily renal: ~60-85% unchanged via glomerular filtration and tubular secretion; ~10% hepatobiliary (bile) and fecal; minor metabolism to penicilloic acid.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic